Investor Presentation Full Year 2017

Investor Presentation Full year 2017 Slide 92 ~50% of historic NovoSevenⓇ sales exposed to competition, but opportunities remain in other indications Estimated NovoSevenⓇ sales by indication¹ CHWI PPX (A&B) CHWI surgery (A&B) CHWI on demand (A&B) Other indications² Challenge ~15% ~25% ~50% Haemophilia A PPx and on demand sales exposed ~10% to competitive entry) ~50% NovoSevenⓇ sales of DKK 9.2 billion³ Opportunities and challenges for NovoSevenⓇ franchise Roche's Emicizumab launched recently, leading to intensified competition in the segment for haemophilia A with inhibitors Opportunities . • • Maintain position as preferred agent for all bleeds including breakthrough bleeds for patients on prophylactic treatment Improving diagnosis and treatment of select indications outside of haemophilia A with inhibitors with special focus on acquired haemophilia Drive development of NovoSevenⓇ franchise in underdeveloped Chinese market following inclusion on National Drug Reimbursement List 1 Based on internal Novo Nordisk estimate 2 Other indications include areas like acquired haemophilia, Glanzmann's thrombastenia and congenital FVII deficiency 3 Reported sales for full year 2017 CHWI: Congenital haemophilia with inhibitors; PPx: Prophylaxis; A&B: Haemophilia A and B novo nordisk

View entire presentation